Tirzepatide Halves Glaucoma Risk Compared to GLP-1 Drugs Alone in 84,000 Diabetic Patients | Research

The takeaway

Tirzepatide was associated with 50% lower POAG risk (RR 0.50), 41% lower OHTN (RR 0.59), and 46% lower glaucoma treatment need (RR 0.54) compared to GLP-1 RAs in 83,698 matched T2D patients.

50% less glaucoma
Tirzepatide users had half the risk of developing primary open-angle glaucoma compared to GLP-1-only drug users

What the researchers found

Tirzepatide vs GLP-1 RA: POAG RR 0.50 (0.34-0.74); OHTN RR 0.59 (0.40-0.88); glaucoma treatment RR 0.54 (0.45-0.64). Consistent with metformin/insulin subgroups and individual GLP-1 RA comparisons. 41,849 matched pairs.

Why it matters

Glaucoma is a leading cause of irreversible blindness affecting 80M people. A 50% risk reduction from a commonly prescribed drug could prevent millions of cases.

How the study worked

Retrospective cohort using 71 US healthcare organizations (June 2022-May 2025), 1:1 propensity matching for demographics, comorbidities, medications, and ophthalmic encounters, with RR calculations.

What this study cannot tell us

Retrospective observational. Cannot prove causation. Short follow-up since tirzepatide approval (2022). Glaucoma diagnosis by codes may miss subclinical cases.

How to read the evidence

Very large propensity-matched cohort with consistent subgroup analyses. Strong signal but observational.

When this study was published

Published in 2025 using data June 2022-May 2025.

The bigger picture

The GIP receptor activation unique to tirzepatide may provide additional neuroprotective effects in the eye beyond GLP-1 agonism alone.

Questions still open

Does GIP receptor activation directly protect retinal ganglion cells?
Should ophthalmologists recommend tirzepatide for patients at glaucoma risk?
Would tirzepatide eye drops provide direct ocular protection?

Common questions

Could tirzepatide protect against glaucoma?

This large study found tirzepatide users had 50% lower glaucoma risk than GLP-1-only drug users. The dual mechanism (GIP+GLP-1) may provide extra eye protection.

Should I switch to tirzepatide to protect my eyes?

This is early evidence — discuss with your doctor. If you have diabetes and glaucoma risk factors, tirzepatide may offer advantages over GLP-1-only drugs, but this needs confirmation.

Read the original research

Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes.

American journal of ophthalmology, 283, 120-128

View on PubMed ↗Publisher’s paper ↗

Citation

Hong, Alexander T; Lin, Forest; Baxter, Sally; Weinreb, Robert N. (2026). Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes.. American journal of ophthalmology, 283, 120-128. https://doi.org/10.1016/j.ajo.2025.12.003